{
  "symbol": "OCGN",
  "company_name": "Ocugen Inc",
  "ir_website": "https://ir.ocugen.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://ir.ocugen.com/press-releases",
          "content": "[ Skip to main content ](#ndq-content)\n\n[ ![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/logo_.svg) ](https://ocugen.com/)\n\n![image description](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-menu-mobile.png)\n\n![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-hero-line01.svg)\n\nBreadcrumb\n\n  * [Home](https://ocugen.com/)\n  * [Investors](/)\n  * press releases\n\n\n\n#  Press Releases \n\n## Press Releases\n\nYear None202420232022202120202019201820172016201520142024\n\n[Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference](/news-releases/news-release-details/ocugen-ceo-present-noblecon20-noble-capital-markets-20th-annual)\n\nMALVERN, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr.\n\nNovember 27, 2024 \n\n[News Release link](/node/13456/pdf)\n\n[Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease](/news-releases/news-release-details/ocugen-announces-european-medicines-agency-grants-orphan)\n\nMALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the European Medicines Agency (EMA) has \n\nNovember 20, 2024 \n\n[News Release link](/node/13436/pdf)\n\n[Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration](/news-releases/news-release-details/ocugen-announces-compelling-preliminary-data-ocu410-single-dose)\n\nMALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced positive preliminary efficacy and safety data \n\nNovember 19, 2024 \n\n[News Release link](/node/13431/pdf)\n\n[Ocugen Provides Business Update with Third Quarter 2024 Financial Results](/news-releases/news-release-details/ocugen-provides-business-update-third-quarter-2024-financial)\n\nConference Call and Webcast Today at 8:30 a.m. ET Subsequent to quarter-end, closed $30 million in debt financing OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) on track to complete enrollment in 1H2025 OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial \n\nNovember 8, 2024 \n\n[News Release link](/node/13371/pdf)\n\n[Ocugen Secures $30 Million in Debt Funding](/news-releases/news-release-details/ocugen-secures-30-million-debt-funding)\n\nMALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that on November 6, 2024, the Company entered \n\nNovember 7, 2024 \n\n[News Release link](/node/13361/pdf)\n\n[Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024](/news-releases/news-release-details/ocugen-clinical-showcase-highlighting-progress-retinal-gene)\n\nProgress on OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP) and new data from Phase 1/2 Preliminary safety and efficacy update on OCU410 Phase 1/2 ArMaDa clinical trial for geographic atrophy (GA) Clinical update on OCU410ST Phase 1/2 GARDian clinical trial for Stargardt \n\nOctober 28, 2024 \n\n[News Release link](/node/13346/pdf)\n\n[Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease](/news-releases/news-release-details/data-and-safety-monitoring-board-approves-initiation-phase-2)\n\nDetermined the high dose of OCU410ST to be the maximum tolerated dose No serious adverse events have been reported Approved proceeding to Phase 2 using high and medium doses of OCU410ST MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a \n\nOctober 22, 2024 \n\n[News Release link](/node/13331/pdf)\n\n[Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results](/news-releases/news-release-details/ocugen-host-conference-call-friday-november-8-830-am-et-0)\n\nMALVERN, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live \n\nOctober 17, 2024 \n\n[News Release link](/node/13316/pdf)\n\n[Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit](/news-releases/news-release-details/ocugen-participate-2024-maxim-healthcare-virtual-summit)\n\nMALVERN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. \n\nOctober 10, 2024 \n\n[News Release link](/node/13296/pdf)\n\n[Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial](/news-releases/news-release-details/ocugen-inc-announces-removal-clinical-hold-investigational-new)\n\nMALVERN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the U.S. \n\nOctober 9, 2024 \n\n[News Release link](/node/13291/pdf)\n\n## Sign up to receive email alerts with the latest news from Ocugen\n\nSubscribe\n"
        }
      ]
    },
    {
      "section_name": "Events and Presentations",
      "links": [
        {
          "title": "Events and Presentations",
          "url": "https://ir.ocugen.com/events-and-presentations",
          "content": "[ Skip to main content ](#ndq-content)\n\n[ ![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/logo_.svg) ](https://ocugen.com/)\n\n![image description](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-menu-mobile.png)\n\n![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-hero-line01.svg)\n\nBreadcrumb\n\n  * [Home](https://ocugen.com/)\n  * [Investors](/)\n  * events and presentations\n\n\n\n#  Events and Presentations \n\n## Events and Presentations\n\n## Upcoming Events and Presentations\n\n[Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference](/events/event-details/noble-capital-markets-20th-annual-emerging-growth-equity-conference)\n\nDecember 3, 2024 at 1:30 PM EST \n\n[Add to Outlook](/node/13461/ics)\n\n[Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text=Ocugen%2C%20Inc.%20-%20Noble%20Capital%20Markets%E2%80%99%2020th%20Annual%20Emerging%20Growth%20Equity%20Conference&dates=20241203T183000Z/20241203T183000Z&details=Event%20Details%3A%20http%3A//ir.ocugen.com/events/event-details/noble-capital-markets-20th-annual-emerging-growth-equity-conference&location=&trp=false&sprop=name%3A)\n\n## Past Events and Presentations\n\nYear None202420232022202120202019None\n\n[ Clinical Showcase](/events/event-details/clinical-showcase-0)\n\nNovember 12, 2024 \n\n[Click here for webcast](https://ocugen.com/videos/Analyst_Day_Nasdaq_11-12-24.mp4)\n\nSupporting Materials\n\n[Ocugen Clinical Showcase 2024](/static-files/2da9d5b7-d77a-4455-9201-54a778aaa81a \"Ocugen Clinical Showcase 2024\") 8.1 MB\n\n[Ocugen, Inc. Third Quarter 2024 Financial Results and Recent Business Highlights](/events/event-details/ocugen-inc-third-quarter-2024-financial-results-and-recent-business-highlights)\n\nNovember 8, 2024 at 8:30 AM EST \n\n[Click here for webcast](https://edge.media-server.com/mmc/p/8wc9qz95)\n\n[2024 Cell & Gene Meeting on the Mesa](/events/event-details/2024-cell-gene-meeting-mesa)\n\nOctober 7, 2024 at 1:30 PM EDT \n\n[Click here for webcast](https://meetingonthemesa.com/)\n\n[Chardan’s 8th Annual Genetic Medicines Conference](/events/event-details/chardans-8th-annual-genetic-medicines-conference)\n\nSeptember 30, 2024 at 10:30 AM EDT \n\n[Click here for webcast](https://wsw.com/webcast/chard19/ocgn/1909908)\n\n[H.C. Wainwright 26th Annual Global Investment Conference](/events/event-details/hc-wainwright-26th-annual-global-investment-conference)\n\nSeptember 9, 2024 at 1:30 PM EDT \n\n[Click here for webcast](https://journey.ct.events/view/131138d2-4ecb-4170-9d30-ad53b57da5cc)\n\n[Ocugen, Inc. Second Quarter 2024 Financial Results and Recent Business Highlights](/events/event-details/ocugen-inc-second-quarter-2024-financial-results-and-recent-business)\n\nAugust 8, 2024 at 8:30 AM EDT \n\n[Click here for webcast](https://edge.media-server.com/mmc/p/24oku5dx)\n\n[H.C. Wainwright 2nd Annual BioConnect Investor Conference](/events/event-details/hc-wainwright-2nd-annual-bioconnect-investor-conference)\n\nMay 20, 2024 at 12:30 PM EDT \n\n[Click here for webcast](https://journey.ct.events/view/245bd49e-dbb1-4dff-8731-fcba5bf1b1e0)\n\n[Ocugen, Inc. First Quarter 2024 Financial Results and Recent Business Highlights](/events/event-details/ocugen-inc-first-quarter-2024-financial-results-and-recent-business-highlights)\n\nMay 14, 2024 at 8:30 AM EDT \n\n[Click here for webcast](https://edge.media-server.com/mmc/p/vp3h8jwm)\n\n[The Citizens JMP Life Sciences Conference](/events/event-details/citizens-jmp-life-sciences-conference)\n\nMay 13, 2024 at 9:30 AM EDT \n\n[Click here for webcast](https://wsw.com/webcast/jmp63/register.aspx?conf=jmp63&page=ocgn&url=https%3A//wsw.com/webcast/jmp63/ocgn/1667952)\n\n[Emerging Growth Virtual Healthcare Equity Conference](/events/event-details/emerging-growth-virtual-healthcare-equity-conference)\n\nApril 17, 2024 at 10:00 AM EDT \n\n[Click here for webcast](https://www.youtube.com/embed/1kus_bgunjY?si=geRNPmHbJivZf4Dq)\n\n## Sign up to receive email alerts with the latest news from Ocugen\n\nSubscribe\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Corporate Governance",
          "url": "https://ir.ocugen.com/corporate-governance",
          "content": "[ Skip to main content ](#ndq-content)\n\n[ ![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/logo_.svg) ](https://ocugen.com/)\n\n![image description](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-menu-mobile.png)\n\n![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-hero-line01.svg)\n\nBreadcrumb\n\n  * [Home](https://ocugen.com/)\n  * [Investors](/)\n  * corporate governance\n\n\n\n#  Corporate Governance \n\n## Corporate Governance\n\n## Overview\n\nThe Board of Directors of Ocugen, Inc. sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.\n\n## Board of Directors\n\n[Kirsten Castillo](/board-member/kirsten-castillo)\n\nDirector\n\n[Prabha Fernandes, Ph.D., FIDSA](/board-member/prabha-fernandes)\n\nLead Director\n\n[Uday B. Kompella, PhD](/board-member/uday-b-kompella-phd)\n\nCo-founder and Director\n\n[Shankar Musunuri, PhD, MBA](/board-member/shankar-musunuri-phd-mba)\n\nChairman of the Board, CEO and Co-founder\n\n[Marna C. Whittington, PhD](/board-member/marna-whittington-phd)\n\nDirector\n\n[Junge (John) Zhang, PhD](/board-member/junge-john-zhang-phd)\n\nDirector\n\n## Governance Documents\n\n[Code of Business Conduct and Ethics](/static-files/b1489ca7-8f2b-4aae-9ec1-2b87716c99b6 \"Code of Business Conduct and Ethics\")\n\n[Corporate Governance Guidelines](/static-files/0e5cb73b-3e39-4b14-9eb0-e238be4244ba \"Corporate Governance Guidelines\")\n\n## Committee Charters\n\n[Audit Committee Charter](/static-files/c25cddcd-b2a2-439f-b2cf-560dcf92b9b9 \"Audit Committee Charter\")\n\n[Compensation Committee Charter](/static-files/b1ec1f38-3e12-4482-975d-7c87720f300d \"Compensation Committee Charter\")\n\n[Nominating and Corporate Governance Committee](/static-files/adfcba74-d1be-41ac-a1a0-aa0590439562 \"Nominating and Corporate Governance Committee\")\n\n[Science and Technology Committee Charter](/static-files/1dd3d37f-a2b7-45aa-80d9-f84616b6e8af \"Science and Technology Committee Charter\")\n\n## Committee Composition\n\n[Audit Committee](/static-files/c25cddcd-b2a2-439f-b2cf-560dcf92b9b9) | [Compensation Committee](/static-files/b1ec1f38-3e12-4482-975d-7c87720f300d) | [Nominating and Corporate Governance Committee](/static-files/adfcba74-d1be-41ac-a1a0-aa0590439562) | [Science and Technology Committee](/static-files/1dd3d37f-a2b7-45aa-80d9-f84616b6e8af)  \n---|---|---|---  \nKirsten Castillo  |  Member [Audit Committee](/static-files/c25cddcd-b2a2-439f-b2cf-560dcf92b9b9) |  Member [Compensation Committee](/static-files/b1ec1f38-3e12-4482-975d-7c87720f300d) |  Chairperson [Nominating and Corporate Governance Committee](/static-files/adfcba74-d1be-41ac-a1a0-aa0590439562) |  Member [Science and Technology Committee](/static-files/1dd3d37f-a2b7-45aa-80d9-f84616b6e8af)  \nPrabha Fernandes, Ph.D., FIDSA  |  Member [Audit Committee](/static-files/c25cddcd-b2a2-439f-b2cf-560dcf92b9b9) |  Chairperson [Compensation Committee](/static-files/b1ec1f38-3e12-4482-975d-7c87720f300d) |  Member [Science and Technology Committee](/static-files/1dd3d37f-a2b7-45aa-80d9-f84616b6e8af)  \nUday B. Kompella, PhD  |  Member [Compensation Committee](/static-files/b1ec1f38-3e12-4482-975d-7c87720f300d) |  Member [Nominating and Corporate Governance Committee](/static-files/adfcba74-d1be-41ac-a1a0-aa0590439562) |  Chairperson [Science and Technology Committee](/static-files/1dd3d37f-a2b7-45aa-80d9-f84616b6e8af)  \nMarna C. Whittington, PhD  |  Chairperson [Audit Committee](/static-files/c25cddcd-b2a2-439f-b2cf-560dcf92b9b9) |  Member [Compensation Committee](/static-files/b1ec1f38-3e12-4482-975d-7c87720f300d)  \nJunge (John) Zhang, PhD  |  Member [Nominating and Corporate Governance Committee](/static-files/adfcba74-d1be-41ac-a1a0-aa0590439562)  \n  \nChairperson Member\n\n## Sign up to receive email alerts with the latest news from Ocugen\n\nSubscribe\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://ir.ocugen.com/sec-filings",
          "content": "[ Skip to main content ](#ndq-content)\n\n[ ![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/logo_.svg) ](https://ocugen.com/)\n\n![image description](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-menu-mobile.png)\n\n![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-hero-line01.svg)\n\nBreadcrumb\n\n  * [Home](https://ocugen.com/)\n  * [Investors](/)\n  * sec filings\n\n\n\n#  SEC Filings \n\n## SEC Filings\n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements3,4,5\n\nFiling year - Any -2024202320222021202020192018201720162015201420132012201120102009200820072006- Any -\n\nItems per page 10255010\n\n[Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | Filing Group | View  \n---|---|---|---|---  \nNovember 26, 2024 | Statement of changes in beneficial ownership of securities | [4](/sec-filings/sec-filing/4/0001062993-24-019706) |  3,4,5 |  [0001062993-24-019706.pdf](/static-files/320a4161-06c5-4c88-b753-5bd6d1ea0626) [0001062993-24-019706.rtf](/static-files/deca5851-b878-460f-b573-ee0c8dd9d56f) [0001062993-24-019706.xls](/static-files/9fcd3d68-094a-4e07-809d-53e25e19eb76) [View HTML](/node/13446/html)  \nNovember 15, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001104659-24-119698) |  Current Reports |  [0001104659-24-119698.pdf](/static-files/12ee3e20-d51d-4d80-aeff-b8a81d46ee36) [0001104659-24-119698.rtf](/static-files/5051bb47-606b-4b0b-851b-a7557bf5a4c1) [0001104659-24-119698.xls](/static-files/938e7a28-80c6-4515-ab3a-c90222ce9205) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001104659-24-119698)[View HTML](/node/13406/html)  \nNovember 15, 2024 | Initial filing by director officer or owner of more than ten percent | [3](/sec-filings/sec-filing/3/0001062993-24-019218) |  3,4,5 |  [0001062993-24-019218.pdf](/static-files/2eb3b072-841f-4cea-bb8b-351abdd0780f) [0001062993-24-019218.rtf](/static-files/69cd84af-ff4c-45db-9863-78fac7801f1b) [0001062993-24-019218.xls](/static-files/de9b5660-2f10-4e9f-ac6a-87430a5ce028) [View HTML](/node/13411/html)  \nNovember 14, 2024 | Quarterly report which provides a continuing view of a company's financial position | [10-Q](/sec-filings/sec-filing/10-q/0001628280-24-047846) |  Quarterly Filings |  [0001628280-24-047846.pdf](/static-files/231d6b18-ee41-4ae8-bff8-dcc90bcdebc7) [0001628280-24-047846.rtf](/static-files/2105aceb-f1c2-4f74-b060-2ec97edc363d) [0001628280-24-047846.xls](/static-files/f83965ea-e319-4cdf-a7b2-12093b3838b7) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001628280-24-047846)[View HTML](/node/13401/html)  \nNovember 12, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001628280-24-046920) |  Current Reports |  [0001628280-24-046920.pdf](/static-files/52d06fb2-2882-46cd-b955-81355f59c560) [0001628280-24-046920.rtf](/static-files/d6ab5336-e507-4a96-b575-69bb6d463e58) [0001628280-24-046920.xls](/static-files/e7b416be-1796-4132-a40a-f427c7c5f7bb) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001628280-24-046920)[View HTML](/node/13391/html)  \nNovember 12, 2024 | An amendment to the SC 13G filing | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000932471-24-001202) |  Other |  [0000932471-24-001202.pdf](/static-files/862a3c2c-ce08-45d6-b8e0-b9810dea51d3) [0000932471-24-001202.rtf](/static-files/ae694faa-68d5-4d11-ae19-1713342c8532) [View HTML](/node/13396/html)  \nNovember 8, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001628280-24-046583) |  Current Reports |  [0001628280-24-046583.pdf](/static-files/3e21418a-87c4-4617-bd16-6c40b43e7e6a) [0001628280-24-046583.rtf](/static-files/721530f7-f793-4946-9444-e3bbeddd8eda) [0001628280-24-046583.xls](/static-files/78a7ac4c-43e2-4bd3-b53a-5733e442b802) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001628280-24-046583)[View HTML](/node/13376/html)  \nNovember 8, 2024 | A statement of beneficial ownership of common stock by certain persons | [SC 13G](/sec-filings/sec-filing/sc-13g/0002012383-24-003506) |  Other |  [0002012383-24-003506.pdf](/static-files/4523c9c1-0d82-48b4-bec9-432a5bfabe93) [0002012383-24-003506.rtf](/static-files/1bdb89fc-ea14-4f36-b867-9dafe54f4e33) [View HTML](/node/13381/html)  \nNovember 8, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001104659-24-115900) |  Current Reports |  [0001104659-24-115900.pdf](/static-files/f3a8b6c9-bf53-4b2f-99c6-8314f82b9130) [0001104659-24-115900.rtf](/static-files/69e864a1-1f2f-4933-a6dc-2c450698e802) [0001104659-24-115900.xls](/static-files/b8528c48-73d7-48ce-a0e9-ddbbc50605e1) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001104659-24-115900)[View HTML](/node/13386/html)  \nNovember 4, 2024 | An amendment to the SC 13G filing | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000932471-24-000643) |  Other |  [0000932471-24-000643.pdf](/static-files/7e3f09f1-e2aa-48fa-8ca6-cab8df75110a) [0000932471-24-000643.rtf](/static-files/370dd0b4-34bc-4282-9335-3330465f4bc3) [View HTML](/node/13351/html)  \n  \nData provided by [Kaleidoscope](https://www.kscope.io).\n\n## Sign up to receive email alerts with the latest news from Ocugen\n\nSubscribe\n"
        }
      ]
    },
    {
      "section_name": "Resources",
      "links": [
        {
          "title": "Investor FAQs",
          "url": "https://ir.ocugen.com/resources/investor-faqs",
          "content": "[ Skip to main content ](#ndq-content)\n\n[ ![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/logo_.svg) ](https://ocugen.com/)\n\n![image description](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-menu-mobile.png)\n\n![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-hero-line01.svg)\n\nBreadcrumb\n\n  * [Home](https://ocugen.com/)\n  * [Investors](/)\n  * investor faqs\n\n\n\n#  Investor FAQs \n\n## Investor FAQs\n\n  * [Where is Ocugen's corporate headquarters?](#)\n\nOcugen’s corporate headquarters are located in Malvern, PA. \n\n  * [Where is the company incorporated?](#)\n\nOcugen is incorporated in the state of Delaware. \n\n  * [What is Ocugen’s fiscal year?](#)\n\nOcugen operates on a fiscal year, with year-end being December 31. \n\n  * [How is Ocugen stock traded?](#)\n\nOcugen is traded on the NASDAQ stock exchange under the symbol “OCGN”. \n\n  * [Who is Ocugen's transfer agent?](#)\n\nOcugen’s transfer agent is Broadridge Financial Solutions, Inc. (Broadridge). You can find more information about how to contact Broadridge at: [https://www.broadridge.com](https://www.broadridge.com/). \n\n  * [How do I report a change the address on my shareholder account?](#)\n\nYou must send both your old and new addresses to our transfer agent, Broadridge Financial Solutions, Inc. by U.S. mail. Each stockholder in question must sign the request for an address change. \n\n  * [How can I replace a lost stock certificate?](#)\n\nPlease contact our transfer agent, Broadridge Financial Solutions, Inc. at (877) 830-4936 or shareholder@broadridge.com. The company can look up your records and make any necessary adjustments. There is generally a fee involved for replacing lost certificates. \n\n  * [Does Ocugen have a direct stock purchase plan?](#)\n\nOcugen does not offer a direct stock purchase plan. \n\n  * [Who is Ocugen's auditor?](#)\n\nPricewaterhouseCoopers LLP \n\n  * [Who is Ocugen's legal counsel?](#)\n\nGoodwin Procter LLP \n\n  * [Where can I get the latest corporate news releases?](#)\n\nYou can view our recent press releases by visiting the [News](/press-releases) section of our website. If you would like to receive email alerts regarding our press releases, please visit our [email alerts](/email-alerts) page. \n\n  * [How can I view documents Ocugen has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?](#)\n\nOcugen’s [SEC filings](/sec-filings) can be accessed under “Financials & Filings” in the “Investors” section of our corporate website or <https://www.sec.gov>\n\n  * [Whom should I contact regarding investor inquiries?](#)\n\nInvestor inquiries should be emailed to IR@ocugen.com. \n\n\n\n\n## Sign up to receive email alerts with the latest news from Ocugen\n\nSubscribe\n"
        },
        {
          "title": "Information Request Form",
          "url": "https://ir.ocugen.com/resources/information-request-form",
          "content": "[ Skip to main content ](#ndq-content)\n\n[ ![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/logo_.svg) ](https://ocugen.com/)\n\n![image description](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-menu-mobile.png)\n\n![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-hero-line01.svg)\n\nBreadcrumb\n\n  * [Home](https://ocugen.com/)\n  * [Investors](/)\n  * information request form\n\n\n\n#  Information Request Form \n\n## Information Request Form\n\nMaterial Selections\n\nInvestor Kit\n\nFirst Name\n\nLast Name\n\nEmail\n\nTitle\n\nCompany\n\nInvestor Type - None -Individual InvestorBuy-Side AnalystSell-Side AnalystPortfolio ManagerStock BrokerEmployeeNews MediaLibraryOther- None -\n\nAddress\n\nCountry - None -AfghanistanÅland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua & BarbudaArgentinaArmeniaArubaAscension IslandAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia & HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCanary IslandsCape VerdeCaribbean NetherlandsCayman IslandsCentral African RepublicCeuta & MelillaChadChileChinaChristmas IslandClipperton IslandCocos (Keeling) IslandsColombiaComorosCongo - BrazzavilleCongo - KinshasaCook IslandsCosta RicaCôte d’IvoireCroatiaCubaCuraçaoCyprusCzechiaDenmarkDiego GarciaDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard & McDonald IslandsHondurasHong Kong SAR ChinaHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacao SAR ChinaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmar (Burma)NamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth KoreaNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian TerritoriesPanamaPapua New GuineaParaguayPeruPhilippinesPitcairn IslandsPolandPortugalPuerto RicoQatarRéunionRomaniaRussiaRwandaSamoaSan MarinoSão Tomé & PríncipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia & South Sandwich IslandsSouth KoreaSouth SudanSpainSri LankaSt. BarthélemySt. HelenaSt. Kitts & NevisSt. LuciaSt. MartinSt. Pierre & MiquelonSt. Vincent & GrenadinesSudanSurinameSvalbard & Jan MayenSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad & TobagoTristan da CunhaTunisiaTurkeyTurkmenistanTurks & Caicos IslandsTuvaluU.S. Outlying IslandsU.S. Virgin IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVatican CityVenezuelaVietnamWallis & FutunaWestern SaharaYemenZambiaZimbabwe- None -\n\nWork Phone\n\nFax\n\nHome Phone\n\nComments\n\nLeave this field blank\n\n## Sign up to receive email alerts with the latest news from Ocugen\n\nSubscribe\n"
        },
        {
          "title": "Investor Contacts",
          "url": "https://ir.ocugen.com/resources/contact-ir",
          "content": "[ Skip to main content ](#ndq-content)\n\n[ ![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/logo_.svg) ](https://ocugen.com/)\n\n![image description](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-menu-mobile.png)\n\n![](/sites/g/files/knoqqb90426/themes/site/nir_pid3422/client/assets/img/bg-hero-line01.svg)\n\nBreadcrumb\n\n  * [Home](https://ocugen.com/)\n  * [Investors](/)\n  * contact ir\n\n\n\n#  Investor Contacts \n\n## Investor Contacts\n\nTiffany Hamilton Head of Communications IR@ocugen.com\n\nName\n\nEmail\n\nSubject\n\nComments\n\nLeave this field blank\n\n## Sign up to receive email alerts with the latest news from Ocugen\n\nSubscribe\n"
        }
      ]
    },
    {
      "section_name": "Corporate Presentation",
      "links": [
        {
          "title": "Corporate Presentation",
          "url": "https://ir.ocugen.com/static-files/33b3d0d8-6fa5-43ed-bd82-412e19d3b6c6",
          "content": "\n"
        }
      ]
    },
    {
      "section_name": "Publications",
      "links": [
        {
          "title": "Publications",
          "url": "https://ocugen.com/publications/",
          "content": "[ ![Ocugen Logo](https://ocugen.com/wp-content/themes/ocugen/images/logo.svg) ](https://ocugen.com)\n\n![](https://ocugen.com/wp-content/themes/ocugen/images/bg-menu-mobile.png)\n\n![](https://ocugen.com/wp-content/uploads/2022/02/bg-hero-line02.svg)\n\n  * [ Home ](https://ocugen.com)\n  * Publications and Posters \n\n\n\n#  Publications and Posters \n\n##  Publications \n\n  * [ OCU400  ![](https://ocugen.com/wp-content/themes/ocugen/images/ico-more.svg) ![](https://ocugen.com/wp-content/themes/ocugen/images/ico-less.svg) ](#!)\n\nJuly 17, 2024\n\n###### [Evaluating therapeutic potential of NR2E3 doses in the rd7 mouse model of retinal degeneration](https://www.nature.com/articles/s41598-024-67095-6)\n\nJanuary 26, 2024\n\n###### [Preclinical dose response study shows NR2E3 can attenuate retinal degeneration in the retinitis pigmentosa mouse model RhoP23H+/−](https://www.nature.com/articles/s41434-024-00440-6)\n\nJune 1, 2023\n\n###### [Drag S, Dotiwala F, Upadhyay AK. Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions. Invest Ophthalmol Vis Sci. Jun 1 2023;64(7):39. doi:10.1167/iovs.64.7.39](https://iovs.arvojournals.org/article.aspx?articleid=2791262)\n\nMarch 2, 2020\n\n###### [Li S, Datta S, Brabbit E, et al. Nr2e3 is a genetic modifier that rescues retinal degeneration and promotes homeostasis in multiple models of retinitis pigmentosa. Gene Ther. May 2021;28(5):223-241. doi:10.1038/s41434-020-0134-z](https://doi.org/10.1038/s41434-020-0134-z)\n\nMay 5, 2016\n\n###### [Olivares AM, Moreno-Ramos OA, Haider NB. Role of Nuclear Receptors in Central Nervous System Development and Associated Diseases. J Exp Neurosci. 2015;9(Suppl 2):93-121. doi:10.4137/JEN.S25480](https://journals.sagepub.com/doi/10.4137/JEN.S25480)\n\nJuly 22, 2009\n\n###### [Schorderet DF, Escher P. NR2E3 mutations in enhanced S-cone sensitivity syndrome (ESCS), Goldmann-Favre syndrome (GFS), clumped pigmentary retinal degeneration (CPRD), and retinitis pigmentosa (RP). Hum Mutat. Nov 2009;30(11):1475-85. doi:10.1002/humu.21096](https://onlinelibrary.wiley.com/doi/10.1002/humu.21096)\n\nMarch 19, 2008\n\n###### [Haider NB, Zhang W, Hurd R, et al. Mapping of genetic modifiers of Nr2e3 rd7/rd7 that suppress retinal degeneration and restore blue cone cells to normal quantity. Mamm Genome. Mar 2008;19(3):145-54. doi:10.1007/s00335-008-9092-2](https://pubmed.ncbi.nlm.nih.gov/18286335/)\n\nJanuary 30, 2007\n\n###### [Haider NB, Demarco P, Nystuen A, et al. The transcription factor Nr2e3 functions in retinal progenitors to suppress cone cell generation. Visual Neuroscience. 2006;23(6):917-929. doi:10.1017/S095252380623027X10-14](https://www.cambridge.org/core/journals/visual-neuroscience/article/abs/transcription-factor-nr2e3-functions-in-retinal-progenitors-to-suppress-cone-cell-generation/467BD0AFF1A683B45D9028EE2C50C027)\n\nJuly 25, 2006\n\n###### [Cheng H, Aleman TS, Cideciyan AV, Khanna R, Jacobson SG, Swaroop A. In vivo function of the orphan nuclear receptor NR2E3 in establishing photoreceptor identity during mammalian retinal development. Human Molecular Genetics. 2006;15(17):2588-2602. doi:10.1093/hmg/ddl185](https://academic.oup.com/hmg/article/15/17/2588/852398)\n\n\n\n\n  * [ OCU410  ![](https://ocugen.com/wp-content/themes/ocugen/images/ico-more.svg) ![](https://ocugen.com/wp-content/themes/ocugen/images/ico-less.svg) ](#!)\n\nMay 16, 2024\n\n###### [Retinoic acid related orphan receptor α is a genetic modifier that rescues retinal degeneration in a mouse model of Stargardt disease and Dry AMD | Gene Therapy (springer.com)](https://link.springer.com/article/10.1038/s41434-024-00455-z?utm_source=rct_congratemailt&utm_medium=email&utm_campaign=oa_20240516&utm_content=10.1038%2Fs41434-024-00455-z)\n\nDecember 5, 2023\n\n###### [Rajanala K, Dotiwala F, Upadhyay A. Geographic atrophy: pathophysiology and current therapeutic strategies. Review. Frontiers in Ophthalmology. 2023-December-05 2023;3doi:10.3389/fopht.2023.1327883](https://doi.org/10.3389/fopht.2023.1327883)\n\nOctober 6, 2011\n\n###### [Jun G, Nicolaou M, Morrison MA, et al. Influence of ROBO1 and RORA on risk of age-related macular degeneration reveals genetically distinct phenotypes in disease pathophysiology. PLoS One. 2011;6(10):e25775. doi:10.1371/journal.pone.0025775](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0025775)\n\n\n\n\n  * [ OCU200  ![](https://ocugen.com/wp-content/themes/ocugen/images/ico-more.svg) ![](https://ocugen.com/wp-content/themes/ocugen/images/ico-less.svg) ](#!)\n\nNovember 6, 2017\n\n###### [Patel PJ, Devonport H, Sivaprasad S, et al. Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update. Clin Ophthalmol. 2017;11:1957-1966. doi:10.2147/OPTH.S145732](https://www.dovepress.com/aflibercept-treatment-for-neovascular-amd-beyond-the-first-year-consen-peer-reviewed-fulltext-article-OPTH)\n\nJanuary 18, 2017\n\n###### [Silva RLE, Kanan Y, Mirando AC, et al. Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage. Sci Transl Med. Jan 18 2017;9(373)doi:10.1126/scitranslmed.aai8030](https://www.science.org/doi/10.1126/scitranslmed.aai8030)\n\nMay 1, 2016\n\n###### [Gunda V, Sudhakar YA. Regulation of Tumor Angiogenesis and Choroidal Neovascularization by Endogenous Angioinhibitors. J Cancer Sci Ther. Jul 4 2013;5(12):417-426. doi:10.4172/1948-5956.1000235](https://www.aaojournal.org/article/S0161-6420\\(16\\)30092-6/fulltext)\n\n###### [Venugopal Gunda and Yakkanti A Sudhakar. Regulation of Tumor Angiogenesis and Choroidal Neovascularization by Endogenous Angioinhibitors. J Cancer Sci Ther.;5(12): 417-426.](https://www.hilarispublisher.com/open-access/regulation-of-tumor-angiogenesis-and-choroidal-neovascularization-by-endogenous-angioinhibitors-1948-5956.1000235.pdf)\n\n\n\n\n  * [ OCU500  ![](https://ocugen.com/wp-content/themes/ocugen/images/ico-more.svg) ![](https://ocugen.com/wp-content/themes/ocugen/images/ico-less.svg) ](#!)\n\nOctober 15, 2024\n\n###### [New Nasal Vaccines Offer Better Protection from COVID and Flu—No Needle Needed](https://www.scientificamerican.com/article/new-nasal-vaccines-offer-stronger-protection-from-covid-flu-and-more-no-needle-needed/)\n\nJuly 31, 2024\n\n###### [Darling, TL, et al. Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters. Science Advances 2024-July-31. 10(31). doi: 10.1126/sciadv.adp1290](https://www.science.org/doi/10.1126/sciadv.adp1290)\n\nOctober 12, 2023\n\n###### [Dotiwala F, Upadhyay AK. Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens. Vaccines. 2023;11(10):1585.](https://www.mdpi.com/2076-393X/11/10/1585)\n\nSeptember 13, 2022\n\n###### [Dotiwala F, Upadhyay AK. A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. Review. Frontiers in Immunology. 2022-September-13 2022;13doi:10.3389/fimmu.2022.940715](https://doi.org/10.3389/fimmu.2022.940715)\n\n\n\n\n##  Posters \n\n  * [ OCU400  ![](https://ocugen.com/wp-content/themes/ocugen/images/ico-more.svg) ![](https://ocugen.com/wp-content/themes/ocugen/images/ico-less.svg) ](#!)\n\nJune 14, 2024\n\n###### [OCU400 Poster](https://ocugen.com/wp-content/uploads/2024/06/Poster-OCU400.pdf)\n\n\n\n\nOcugen’s website uses cookies to enhance site navigation and analyze site usage. By clicking “Accept Cookies” or continuing to use this website, you are agreeing to our use of cookies. Click here to see our [Cookie Policy](#!)\n\n[ Accept Cookies ](#!)\n"
        }
      ]
    }
  ]
}